Summit Therapeutics plc (SMMT): Price and Financial Metrics


Summit Therapeutics plc (SMMT)

Today's Latest Price: $3.42 USD

0.09 (2.70%)

Updated Sep 25 3:59pm

Add SMMT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

SMMT Stock Summary

  • The ratio of debt to operating expenses for Summit Therapeutics plc is higher than it is for about only 0.42% of US stocks.
  • With a year-over-year growth in debt of -100%, Summit Therapeutics plc's debt growth rate surpasses merely 0% of about US stocks.
  • Revenue growth over the past 12 months for Summit Therapeutics plc comes in at 1,893.29%, a number that bests 99.56% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Summit Therapeutics plc, a group of peers worth examining would be VYGR, ANAB, CRBP, CARA, and NVAX.
  • Visit SMMT's SEC page to see the company's official filings. To visit the company's web site, go to www.summitplc.com.
SMMT Daily Price Range
SMMT 52-Week Price Range

SMMT Stock Price Chart Technical Analysis Charts


SMMT Price/Volume Stats

Current price $3.42 52-week high $5.49
Prev. close $3.33 52-week low $1.18
Day low $3.31 Volume 21,376
Day high $3.42 Avg. volume 119,147
50-day MA $3.51 Dividend yield N/A
200-day MA $2.78 Market Cap 109.78M

Summit Therapeutics plc (SMMT) Company Bio


Summit Therapeutics plc operates as a biopharmaceutical company primarily in the United Kingdom and the Unites States. It focuses on the discovery, development, and commercialization of novel medicines to treat the Duchenne Muscular Dystrophy (DMD), a fatal muscle wasting disease; and infections caused by Clostridium difficile bacteria (CDI). The company was founded in 2003 and is based in Abingdon, England.


SMMT Latest News Stream


Event/Time News Detail
Loading, please wait...

SMMT Latest Social Stream


Loading social stream, please wait...

View Full SMMT Social Stream

Latest SMMT News From Around the Web

Below are the latest news stories about Summit Therapeutics Inc that investors may wish to consider to help them evaluate SMMT as an investment opportunity.

Summit Announces Effectiveness of Scheme of Arrangement and Completion of Redomiciliation to Delaware, USA

Summit Therapeutics Inc.(“Summit” or the “Company”)Summit Announces Effectiveness of Scheme of Arrangement and Completion of Redomiciliation to Delaware, USACambridge, MA, September 18, 2020 – Summit (NASDAQ: SMMT) today announces the completion of the company’s redomiciliation to Delaware, USA. Previously, Summit Therapeutics plc announced that the High Court of Justice in England and Wales had sanctioned the scheme of arrangement under Part 26 of the Companies Act 2006 (the “Scheme”) pursuant to which Summit Therapeutics Inc. is becoming the new Delaware, USA incorporated holding company of Summit Therapeutics plc and its subsidiaries.  Following the delivery today of the Court Order to the Registrar of Companies in the U.K., the Scheme has become effective and every five ordinary sha...

Yahoo | September 18, 2020

Summit Announces Intention to Redomicile its Holding Company to the United States

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Announces Intention to Redomicile its Holding Company to the United States Oxford, UK, and Cambridge, MA,.

Yahoo | July 16, 2020

Summit Therapeutics announces publication of ridinilazole data

Thinly traded micro cap Summit Therapeutics ([[SMMT]] +0.5%) is in the green, albeit trailing the broad market and on turnover of only 9.3K shares, on the heels of the publication of data from a Phase 2 clinical trial, CoDIFy, (that ended in October 2015) comparing small molecule antibiotic ridinilazole to vancomycin...

Seeking Alpha | July 13, 2020

Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health Oxford, UK, and Cambridge,.

Yahoo | July 13, 2020

Summit appoints Michael Donaldson as CFO

Summit Therapeutics (SMMT) has appointed Mr. Michael Donaldson as Chief Financial Officer, effective immediately. Mr. Donaldson joins Summit from Goldfinch Bio, Inc., where he served as Vice President, Finance, and Corporate Controller....

Seeking Alpha | June 8, 2020

Read More 'SMMT' Stories Here

SMMT Price Returns

1-mo -2.84%
3-mo 12.50%
6-mo 44.30%
1-year 123.53%
3-year -73.34%
5-year -67.12%
YTD 113.75%
2019 39.13%
2018 -89.62%
2017 29.44%
2016 -25.57%
2015 N/A

Continue Researching SMMT

Here are a few links from around the web to help you further your research on Summit Therapeutics plc's stock as an investment opportunity:

Summit Therapeutics plc (SMMT) Stock Price | Nasdaq
Summit Therapeutics plc (SMMT) Stock Quote, History and News - Yahoo Finance
Summit Therapeutics plc (SMMT) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.6797 seconds.